Tomo Osako

Summary

Affiliation: Cancer Institute Hospital
Country: Japan

Publications

  1. ncbi Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Cancer Chemother Pharmacol 63:865-71. 2009
  2. ncbi High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy
    Tomo Osako
    Divisions of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:1431-8. 2010
  3. ncbi Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:233-41. 2010
  4. ncbi Histogenesis of metaplastic breast carcinoma and axillary nodal metastases
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Koto ku, Tokyo, Japan
    Pathol Int 59:116-20. 2009
  5. ncbi Accurate staging of axillary lymph nodes from breast cancer patients using a novel molecular method
    T Osako
    Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
    Br J Cancer 105:1197-202. 2011
  6. ncbi Acute radiation dermatitis and pneumonitis in Japanese breast cancer patients with whole breast hypofractionated radiotherapy compared to conventional radiotherapy
    Tomo Osako
    Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo 135 8550, Japan
    Jpn J Clin Oncol 38:334-8. 2008
  7. ncbi Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo 135 8550, Japan
    Cancer Chemother Pharmacol 62:159-64. 2008
  8. ncbi Diagnostic mammography and ultrasonography for palpable and nonpalpable breast cancer in women aged 30 to 39 years
    Tomo Osako
    Department of Breast Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan
    Breast Cancer 14:255-9. 2007
  9. ncbi Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
    Tumori 93:129-32. 2007
  10. ncbi Diagnostic ultrasonography and mammography for invasive and noninvasive breast cancer in women aged 30 to 39 years
    Tomo Osako
    Department of Breast Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
    Breast Cancer 14:229-33. 2007

Detail Information

Publications15

  1. ncbi Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Cancer Chemother Pharmacol 63:865-71. 2009
    ....
  2. ncbi High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy
    Tomo Osako
    Divisions of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:1431-8. 2010
    ..To determine the highly sensitive and highly resistant subsets to cytotoxic chemotherapy, we evaluated predictive factors for pCR and PD to NAC, and assessed the similarities in these factors...
  3. ncbi Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:233-41. 2010
    ....
  4. ncbi Histogenesis of metaplastic breast carcinoma and axillary nodal metastases
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Koto ku, Tokyo, Japan
    Pathol Int 59:116-20. 2009
    ..This suggested that the ductal component metastasized to the nodes and that epithelial-mesenchymal transition subsequently occurred within the nodes...
  5. ncbi Accurate staging of axillary lymph nodes from breast cancer patients using a novel molecular method
    T Osako
    Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
    Br J Cancer 105:1197-202. 2011
    ..We aimed to determine the performance of the OSNA assay as an accurate nodal staging tool in comparison with routine histological examination...
  6. ncbi Acute radiation dermatitis and pneumonitis in Japanese breast cancer patients with whole breast hypofractionated radiotherapy compared to conventional radiotherapy
    Tomo Osako
    Department of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo 135 8550, Japan
    Jpn J Clin Oncol 38:334-8. 2008
    ..To evaluate acute morbidity, radiation dermatitis and pneumonitis, of Japanese patients treated with whole breast hypofractionated radiotherapy (RT) after breast-conserving surgery (BCS), compared to conventional RT...
  7. ncbi Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo 135 8550, Japan
    Cancer Chemother Pharmacol 62:159-64. 2008
    ..We retrospectively evaluated the efficacy and safety of combination therapy of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer (MBC)...
  8. ncbi Diagnostic mammography and ultrasonography for palpable and nonpalpable breast cancer in women aged 30 to 39 years
    Tomo Osako
    Department of Breast Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan
    Breast Cancer 14:255-9. 2007
    ..To investigate the relationship between the tumor size of breast cancer by palpation and the sensitivity of mammography (MMG) and ultrasonography (US), and which modality can detect nonpalpable breast cancer in women aged 30 to 39 years...
  9. ncbi Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
    Tumori 93:129-32. 2007
    ..The purpose of the present retrospective study was to evaluate efficacy and safety of a lower dose-intensity capecitabine monotherapy regimen in heavily pretreated patients with metastatic breast cancer...
  10. ncbi Diagnostic ultrasonography and mammography for invasive and noninvasive breast cancer in women aged 30 to 39 years
    Tomo Osako
    Department of Breast Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
    Breast Cancer 14:229-33. 2007
    ....
  11. ncbi Flare-up of dermatomyositis along with recurrence of breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Breast J 13:200-2. 2007
    ....
  12. ncbi Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology
    Tomo Osako
    Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer 117:4365-74. 2011
    ..The authors compared the performance in intraoperative detection of sentinel lymph node metastases with OSNA assay using a whole lymph node versus routine frozen section (FS) histology with a 2 mm-sectioned lymph node...
  13. ncbi Apocrine metaplasia of breast cancer: clinicopathological features and predicting response
    Akiko Ogiya
    Department of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, Koto ku, Tokyo, Japan
    Breast Cancer 17:290-7. 2010
    ..We thus considered that apocrine metaplasia (AM) might represent a predictive marker for breast cancer...
  14. ncbi Clinicopathological significance of invasive micropapillary carcinoma component in invasive breast carcinoma
    Yoshimi Ide
    Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
    Pathol Int 61:731-6. 2011
    ..The presence of IMP components was a significant predictive factor for nodal metastasis, even if it is detected in only a small proportion of the tumor...
  15. ncbi Intraperitoneal rupture of the ureter as a cause of generalized peritonitis: report of a case
    Tomo Osako
    Department of Surgery, Ayabe Municipal Hospital, Kyoto, Japan
    Surg Today 36:839-42. 2006
    ..Image-guided interventions play a crucial role in the management of ureteral urine leaks after a correct diagnosis has been made...